| Name | Title | Contact Details |
|---|
Option Six, Inc. is a Bloomington, IN-based company in the Software and Internet sector.
Editorial Services Co is a Louisville, KY-based company in the Software and Internet sector.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
LiquidM is the only white-labeled Mobile Advertising Management Platform (MAMP), which allows media buyers to optimize their processes across the full range of premium to performance advertising. Build from the ground up for mobile, LiquidM’s white-labeled Mobile Advertising Management Platform (MAMP) allows mobile media buyers to optimize their management processes across the full range of premium to performance advertising. LiquidM provides a business model-agnostic full stack to manage and optimize mobile advertising campaigns. LiquidM’s modular, cloud-based SaaS replaces Build-Your-Own (BYO) or inadequate point solutions of ad tech infrastructure with a standardized, open platform that is customizable to individual needs. LiquidM’s unique combination of delivering quality and performance in one platform allows for reach extension through real-time bidding, targeting, rich media formats and the ability to work closely with mobile operators.